Healthcare · NSE: TORNTPHARM · BSE: 500420
Torrent Pharma: how the business works
Torrent Pharma makes branded medicines for India and Brazil and generic medicines for the US and Germany, earning ₹13,980 crore of revenue in FY26.
Follow Torrent Pharma
Email me when Torrent Pharma's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Torrent Pharmaceuticals Limited · Ahmedabad, Gujarat · Founded 1959
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹13,980 cr
- Profit to shareholders, FY26
- ₹2,163 cr
- India sales force, 30 Sep 2026
- 9,100
- Started (as Trinity Laboratories)
- 1959
- Promoter holding, 30 Sep 2026
- 60.78%
The short version
Torrent Pharma in 5 points
1 · What it sells
Torrent Pharma sells branded medicines in India and Brazil and generic medicines in the US and Germany, and its FY26 revenue from operations was ₹13,980 crore.
2 · Who pays it
In FY26, customers in India paid 58.4% of Torrent's revenue, the US 9.7%, Brazil 9.7%, Germany and Malta 8.9% and other countries 13.2%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Torrent kept ₹15.6 as profit, after ₹89 crore of one-off costs (mostly for the JB deal) and a ₹94 crore net loss in other income, while its EBITDA, which leaves out other income, was 32.0% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Torrent reports a single segment, so it does not say which market earns its FY26 EBITDA of ₹4,470 crore (Cityfort calculation), but for Q1 FY27 it gave operating EBITDA of ₹1,240 crore for its base business and ₹424 crore for JB.
5 · The one thing to watch
Torrent's borrowings were ₹13,874 crore on 30 Sep 2026, up from ₹3,026 crore on 31 Mar 2025, and its interest cost was ₹300 crore in Q2 FY27 against ₹48 crore in Q2 FY26.
Sources: From Torrent Pharma's FY26 annual report, its FY26 and Q2 FY27 results filings, and its Q1 FY27 results release · checked
Sources (7)
- Integrated Annual Report 2025-26 (FY26)
- Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
- Press release: Torrent Pharma announces Q1 FY27 results (with results filing)
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25
- Integrated filing (financials) XBRL, consolidated, Q2 FY26
01Where the money goes · FY26
Where does ₹100 of Torrent Pharma's money go?
Torrent Pharma · FY26
Receipt for every ₹100
| Materials and goods bought | ₹24.4 |
|---|---|
| Employee costs | ₹19.2 |
| Other running costs | ₹24.2 |
| Depreciation, amortisation and interest | ₹10.8 |
| One-off costs (mostly JB deal costs) | ₹0.6 |
| Income tax | ₹5.3 |
| Kept as profit for shareholders | ₹15.6 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 results: each line ÷ total money in × 100. Money in = revenue of ₹13,980 crore minus the ₹94 crore net loss in other income = ₹13,886 crore. Profit is the shareholders' share: ₹25 crore more than money in minus the costs shown, because JB's minority shareholders took ₹25 crore of losses before the merger.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Torrent Pharma do?
Distributors, pharmacies and hospitals in more than 50 markets, most of all India, pay Torrent Pharma for its medicines; materials, running costs and staff take most of the money, and ₹15.6 of every ₹100 that came in was left as profit in FY26.
- In FY26 customers in India gave 58.4% of Torrent's revenue, the US 9.7%, Brazil 9.7%, Germany and Malta 8.9% and other countries 13.2%.
- Of every ₹100 that came in during FY26, ₹24.4 went on materials and goods bought, ₹24.2 on other running costs and ₹19.2 on staff.
03Who pays it
Who pays Torrent Pharma?
Customers in India
58.4%
of revenue
Wholesale distributors, stockists, pharmacies, online sellers and institutions such as hospitals, which sell to patients on doctors' prescriptions. Share is of FY26 revenue by customer location (₹8,161 crore); the India business unit reported ₹7,645 crore.
Customers in the US
9.7%
of revenue
Buyers of Torrent's generic medicines in the US: ₹1,363 crore in FY26, against ₹1,100 crore in FY25.
Customers in Brazil
9.7%
of revenue
Buyers of Torrent's branded generics in Brazil: ₹1,362 crore in FY26.
Customers in Germany and Malta
8.9%
of revenue
Buyers of Torrent's generic medicines in Germany, including through tenders: ₹1,249 crore in FY26.
Customers in other countries
13.2%
of revenue
Buyers in more than 50 markets in all, and companies that pay for contract manufacturing: ₹1,845 crore in FY26.
- Customers in India58.4%
- Customers in the US9.7%
- Customers in Brazil9.7%
- Customers in Germany and Malta8.9%
- Customers in other countries13.2%
How spread out the customers are
No single customer gave Torrent 10% or more of its revenue in FY26 or FY25, according to its segment note. On 31 Mar 2025 one Latin America-based distributor owed more than 10% of trade receivables; none did on 31 Mar 2026.
04How it makes money
How does Torrent Pharma make money?
Prescription brands keep Torrent's gross margin near 76%; since the JB deal, amortisation and interest take a bigger share of profit.
Gross margin stayed between 75.3% and 76.4% in each of the eight quarters to Q2 FY27 (Cityfort calculation). The company links the rise in depreciation, amortisation and interest in FY26 to the JB acquisition. Net profit per ₹100 of revenue fell from ₹19.2 in Q3 FY26 to ₹10.7 in Q2 FY27.
Net profit per ₹100 of revenue
₹19.2₹10.7
Q3 FY26 to Q2 FY27
- Doctors prescribe Torrent's brands; chronic and sub-chronic medicines were about 76% of FY25 India revenue, ICRA says.
- Gross margin stayed between 75.3% and 76.4% in each of the eight quarters to Q2 FY27 (Cityfort calculation).
- In Jan–Feb 2026 Torrent paid ₹12,537 crore for 48.80% of JB Pharma, after issuing ₹10,990 crore of NCDs.
- Depreciation, amortisation and interest were ₹909 crore in Q2 FY27 against ₹252 crore in Q2 FY26 (Cityfort calculation); the company links the rise to the JB acquisition.
- EBITDA margin held at 33.3% in Q2 FY27, while net margin fell to 10.7%.
- Net debt fell from ₹12,767 crore on 31 Mar 2026 to ₹10,888 crore on 30 Sep 2026.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Torrent Pharma?
India
54.7%Branded prescription medicines and Curatio's skin-care brands; business-unit figures from the annual report, as Torrent reports one audited segment. FY26 includes JB from 21 Jan 2026.
Revenue ₹7,645 cr
Brazil
9.7%Branded generics in Brazil.
Revenue ₹1,362 cr
USA
9.7%Generic medicines in the US.
Revenue ₹1,363 cr
Germany
8.9%Generic medicines in Germany, partly sold through tenders.
Revenue ₹1,249 cr
Others
16.9%Other countries and contract manufacturing. FY22 and FY23 add the annual reports' 'Other countries' and 'Others' rows (Cityfort calculation); FY25 and FY26 reports merge them.
Revenue ₹2,361 cr
How the mix changed
- India
- Brazil
- USA
- Germany
- Others
Revenue by segment, FY22 to FY26.
₹ crore
See the numbers
Sources (7)
- Annual Report 2021-22 (FY22)
- Annual Report 2022-23 (FY23)
- Annual Report 2023-24 (FY24)
- Annual Report 2024-25 (FY25)
- Integrated Annual Report 2025-26 (FY26)
- Investor presentation: audited results for Q4 FY26 and FY26 (filed with NSE)
- ICRA rationale: Torrent Pharmaceuticals Limited, change in limits (21 Jul 2026)
06The numbers · Consolidated · ₹ crore
How has Torrent Pharma done?
Revenue
₹13,980 crFY26
Revenue rose every year, from ₹8,508 crore in FY22 to ₹13,980 crore in FY26, but FY26 and later periods include JB Pharma from 21 Jan 2026 and earlier periods are not restated, so growth across that break is not like for like: the company put FY26 growth at 21% reported and 15% excluding JB.
₹ crore
See the numbers
Net profit
₹2,163 crFY26
Profit for shareholders rose from ₹777 crore in FY22, after a ₹485 crore write-down of a US plant, to ₹2,163 crore in FY26, and was ₹534 crore in Q2 FY27 against ₹591 crore in Q2 FY26, but FY26 and later periods include JB Pharma from 21 Jan 2026 and earlier periods are not restated, so these comparisons are not like for like; the company links the rise in amortisation and interest to the JB acquisition.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹15.5FY26
EBITDA (Cityfort calculation on profit after one-off items) was 22.9% of revenue in FY22, after the ₹485 crore US plant write-down, and 32.0% in FY26, after ₹89 crore of one-off costs (₹70 crore of them for the JB deal), while net profit per ₹100 of revenue fell from ₹16.6 in FY25 to ₹15.5 in FY26 and ₹10.7 in Q2 FY27.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹2,346 crFY26
Free cash flow (cash from operations minus capital spending) was ₹2,346 crore in FY26, against ₹1,974 crore in FY25; separately, Torrent spent ₹12,315 crore (net of cash acquired) buying JB in FY26 and borrowed ₹12,594 crore that year.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners. Total net income differs from net profit to the company's owners: Total profit of ₹2,138 crore is ₹25 crore less than the shareholders' share because JB Pharma's minority shareholders took ₹25 crore of losses between 21 Jan and 31 Mar 2026.
Sources (17)
- Financial results XBRL, consolidated, Q4 FY22 and FY22
- Annual Report 2021-22 (FY22)
- Annual Report 2022-23 (FY23)
- Financial results XBRL, consolidated, Q4 FY23 and FY23
- Financial results XBRL, consolidated, Q4 FY24 and FY24
- Annual Report 2023-24 (FY24)
- Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25
- Annual Report 2024-25 (FY25)
- Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26
- Integrated Annual Report 2025-26 (FY26)
- Financial results XBRL, consolidated, Q3 FY25
- Integrated filing (financials) XBRL, consolidated, Q1 FY26
- Integrated filing (financials) XBRL, consolidated, Q2 FY26
- Integrated filing (financials) XBRL, consolidated, Q3 FY26
- Integrated filing (financials) XBRL, consolidated, Q1 FY27
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
07Who runs it
Who runs Torrent Pharma, and did they deliver?
Samir Mehta
Executive Chairman
Aman Mehta
Managing Director · since 2025
From 1 Aug 2025, for five years.
Sudhir Menon
Executive Director (Finance) and Chief Financial Officer
Sanjay Gupta
Executive Director, International
Runs the business outside India.
Chintan Trivedi
Company Secretary
What they said, and what happened
4 too early to tell
Said on 13 Feb 2026
CFO Sudhir Menon said that, if he remembered the numbers correctly, net debt would be around 1 to 1.1 times EBITDA in FY28 and around 0.6 times in FY29, "plus minus here and there".
Too early to tellWhat happened
Sudhir Menon said on 23 Oct 2026 that net debt to EBITDA was 1.8 times at the end of Q2 FY27, after 2.07 times at Q1 FY27.
Said on 22 May 2026
Management said it had guided for cost savings from the JB merger of up to ₹450 crore by year 3, and about 20% of that in year 1.
Too early to tellWhat happened
On 30 Jul 2026 management said it could not share the exact number, but year 1 was "going to be above 90" crore and "definitely going to be above 100". On 23 Oct 2026 Aman Mehta said cost savings were tracking well ahead of plan.
Said on 30 Jul 2026
Aman Mehta said that with ₹50 crore of semaglutide sales in Q1 FY27, Torrent was "well on track to achieve our INR250 crores target for the year in absence of the supply issue".
Too early to tellWhat happened
Semaglutide market share was 32% in Q2 FY27, against 36% in Q1; Aman Mehta said injectable supply was fully restored by Sep 2026. The company has not given a Q2 FY27 semaglutide sales figure in the documents checked.
Said on 23 Oct 2026
Sanjay Gupta said Torrent had 53 molecules under review by ANVISA in Brazil and expected approval in the next 3 years.
Too early to tellWhat happened
The number under review was 65 in Q2 FY26, 60 in Q3 FY26, 58 in Q1 FY27 and 53 in Q2 FY27.
Sources (9)
- Integrated Annual Report 2025-26 (FY26)
- Q2 FY27 earnings call transcript (call 23 Oct 2026)
- Q3 FY26 earnings call transcript (call 13 Feb 2026)
- Q1 FY27 earnings call transcript (call 30 Jul 2026)
- Q4 FY26 earnings call transcript (call 22 May 2026)
- Press release: Torrent Pharma announces Q2 FY27 results
- Press release: Torrent Pharma announces Q2 FY26 results
- Press release: Torrent Pharma announces Q3 FY26 results
- Press release: Torrent Pharma announces Q1 FY27 results (with results filing)
08What could go wrong
What could go wrong for Torrent Pharma?
- Debt
Debt taken on for JB
Borrowings were ₹13,874 crore on 30 Sep 2026, against ₹3,026 crore on 31 Mar 2025. Interest cost was ₹300 crore in Q2 FY27, against ₹48 crore in Q2 FY26; the CFO put the average interest cost at about 7.6% in Feb 2026.
Watch Net debt each half-year (₹10,888 crore on 30 Sep 2026) and the company's net debt to EBITDA (1.8 times at Q2 FY27).
- Execution
Joining JB into Torrent
JB's revenue was largely flat at ₹1,086 crore in Q2 FY27 and its international business fell 7%. The company said merging sales teams, plants and quality systems had a "transient impact" and postponed some deliveries.
Watch JB revenue each quarter (₹1,201 crore in Q1 FY27, ₹1,086 crore in Q2 FY27).
- Other
Amortisation and goodwill
Depreciation and amortisation was ₹609 crore in Q2 FY27, against ₹204 crore in Q2 FY26. On 30 Sep 2026 goodwill (₹3,990 crore) and other intangible assets (₹23,352 crore) together exceeded net worth of ₹18,373 crore.
Watch Depreciation and amortisation each quarter, and any write-down of goodwill or intangibles.
- Competition
Lost tenders and a supplier problem in Germany
Germany revenue was €26 million in Q2 FY27, down 13% in constant currency. Sanjay Gupta cited the loss of high-value tenders and disruption at third-party suppliers.
Watch Germany revenue in euros and its constant-currency growth each quarter.
- Regulation
Waiting for approvals in Brazil
53 Torrent products were under review by ANVISA in Q2 FY27. Brazil revenue rose 3% in local currency in Q1 FY27, which the company linked to a one-time cut in channel stock, and 20% in Q2 FY27.
Watch The number of products under ANVISA review and Brazil revenue in local currency.
- Concentration
Relying on a partner for semaglutide injections
A manufacturing partner's supply problem kept Torrent's semaglutide injections off the market for nearly two months in 2026; a new partner restored supply by Sep 2026. Combined market share went from 36% in Q1 FY27 to 32% in Q2 FY27.
Watch Semaglutide market share in each quarter's call.
- Currency
Currency swings
About 41% of FY26 revenue came from exports (BRSR). Other income, which nets foreign-exchange gains and losses, was negative in every quarter from Q4 FY25 to Q2 FY27 and −₹94 crore for FY26.
Watch Other income in each quarter's results (−₹10 crore in Q2 FY27).
Sources (10)
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25
- Integrated filing (financials) XBRL, consolidated, Q2 FY26
- Q3 FY26 earnings call transcript (call 13 Feb 2026)
- Q2 FY27 earnings call transcript (call 23 Oct 2026)
- Press release: Torrent Pharma announces Q2 FY27 results
- Press release: Torrent Pharma announces Q1 FY27 results (with results filing)
- Q1 FY27 earnings call transcript (call 30 Jul 2026)
- Integrated Annual Report 2025-26 (FY26)
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year, from ₹8,508 crore in FY22 to ₹13,980 crore in FY26, and Torrent's business excluding JB grew 18% in Q2 FY27, the company said.
- Gross margin stayed between 75.3% and 76.4% in each of the eight quarters to Q2 FY27, and EBITDA margin was 33.3% in Q2 FY27 (Cityfort calculations).
- The FY26 annual report ranks Torrent with JB 1st in India's heart medicines and 5th in the Indian medicine market.
- Net debt fell from ₹12,767 crore on 31 Mar 2026 to ₹10,888 crore on 30 Sep 2026, and India Ratings revised its outlook to Positive on 7 Oct 2026.
- No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
What critics point to
- Borrowings were ₹13,874 crore on 30 Sep 2026, against ₹3,026 crore on 31 Mar 2025, and quarterly interest cost rose from ₹48 crore in Q2 FY26 to ₹300 crore in Q2 FY27.
- Q2 FY27 profit for shareholders was ₹534 crore, below ₹591 crore a year earlier, though revenue rose from ₹3,302 crore to ₹4,979 crore.
- JB's revenue was largely flat in Q2 FY27 at ₹1,086 crore, and its international business fell 7%.
- Germany revenue fell 13% in constant currency in Q2 FY27; the company cited lost tenders and a supplier disruption.
- Goodwill and other intangible assets of ₹27,342 crore exceeded net worth of ₹18,373 crore on 30 Sep 2026 (Cityfort calculation).
10What to watch next
What should you watch next at Torrent Pharma?
Next event
Q3 FY27 results
Date not announced yet.
JB's revenue
JB brought in ₹1,086 crore in Q2 FY27, largely flat; the company called the integration impact transient.
Net debt and leverage
Net debt was ₹10,888 crore on 30 Sep 2026, 1.8 times EBITDA by the company's measure; the CFO said in Feb 2026 he expected around 1 to 1.1 times in FY28.
Germany and semaglutide
Germany revenue fell 13% in constant currency in Q2 FY27, and semaglutide market share went from 36% in Q1 FY27 to 32% in Q2 FY27.
11Key facts
Key facts about Torrent Pharma
- What does Torrent Pharma do?
- Torrent Pharmaceuticals Ltd is an Ahmedabad-based drug maker that sells branded medicines in India and Brazil and generic medicines in the US and Germany. Torrent Pharma's FY26 revenue from operations was ₹13,980 crore, and its FY26 annual report lists 8 manufacturing plants in India, not counting those that came with JB Pharma.
- How does Torrent Pharma make money?
- Torrent Pharma sells medicines that doctors prescribe, mostly under its own brand names. By the FY26 annual report's business-unit figures, Torrent Pharma's India business sold ₹7,645 crore in FY26, Brazil ₹1,362 crore, the US ₹1,363 crore, Germany ₹1,249 crore and other markets ₹2,361 crore.
- Who are Torrent Pharma's customers?
- By customer location, Torrent Pharma's FY26 revenue came 58.4% from customers in India, 9.7% from the US, 9.7% from Brazil, 8.9% from Germany and Malta and 13.2% from other countries. No single customer gave Torrent Pharma 10% or more of its revenue in FY26 or FY25.
- How big is Torrent Pharma?
- Torrent Pharma's FY26 revenue from operations was ₹13,980 crore and its profit for shareholders was ₹2,163 crore. Torrent Pharma had 18,531 employees at the end of FY26, not counting JB Pharma's staff.
- Who owns Torrent Pharma?
- On 30 Sep 2026 Torrent Pharma's promoter group, led by the holding company Torrent Investments, held 60.78% of the shares. Foreign institutions held 17.22%, Indian institutions 13.46% (mutual funds 8.82%) and other shareholders 8.54%. No promoter shares were pledged.
- What is Torrent Pharma's JB Pharma deal?
- Torrent Pharma bought control of J. B. Chemicals & Pharmaceuticals (JB Pharma) on 21 Jan 2026; by 3 Feb 2026 it had paid ₹12,537 crore for 48.80% of JB. JB Pharma then merged into Torrent Pharma with effect from 8 Jul 2026, and Torrent Pharma issued 41,922,416 new shares to JB's other shareholders on 20 Jul 2026.
- How did Torrent Pharma do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Torrent Pharma's revenue was ₹4,979 crore, up from ₹3,302 crore a year earlier, and profit for shareholders was ₹534 crore, down from ₹591 crore. Q2 FY27 includes JB Pharma (₹1,086 crore of revenue) and Q2 FY26 does not; the company said its business excluding JB grew 18%.
- How much debt does Torrent Pharma have?
- On 30 Sep 2026 Torrent Pharma had borrowings of ₹13,874 crore and cash and liquid investments of ₹2,986 crore, against borrowings of ₹3,026 crore on 31 Mar 2025. India Ratings affirmed Torrent Pharma at IND AA+ and changed its outlook to Positive, the company told the exchanges on 7 Oct 2026.
- Why did Torrent Pharma's promoter holding fall to 60.78%?
- Torrent Pharma's promoter holding fell from 68.31% to 60.78% on 20 Jul 2026 because Torrent Pharma issued 41,922,416 new shares to JB Pharma's shareholders under the merger; the promoter group's 231,185,400 shares did not change. Earlier, on 30 Oct 2024, Torrent Investments sold 2.94% of Torrent Pharma, taking the holding from 71.25% to 68.31%.
- What dividend does Torrent Pharma pay?
- Torrent Pharma's dividend for FY26 was ₹38 per share: an interim ₹29 and a final ₹9 recommended on 22 May 2026. That was 59.4% of Torrent Pharma's FY26 basic earnings per share of ₹63.92 (Cityfort calculation from the FY26 annual report).
Sources (14)
- Integrated Annual Report 2025-26 (FY26)
- Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26
- Investor presentation: audited results for Q4 FY26 and FY26 (filed with NSE)
- Shareholding pattern as of 30 Sep 2026
- Scheme of amalgamation of J. B. Chemicals & Pharmaceuticals with Torrent: effective date 8 Jul 2026
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Integrated filing (financials) XBRL, consolidated, Q2 FY26
- Press release: Torrent Pharma announces Q2 FY27 results
- Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25
- Intimation of credit rating: India Ratings affirms IND AA+, outlook revised to Positive
- Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment)
- SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024
- Q4 FY26 earnings call transcript (call 22 May 2026)
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Torrent Pharma sell?
Branded medicines in India
Prescription brands, many for long-term conditions such as heart disease and diabetes: ₹7,645 crore of revenue in FY26, including JB Pharma from 21 Jan 2026. The FY26 annual report says Torrent with JB ranks 1st in heart medicines in India and 5th in the Indian medicine market overall.
Branded generics in Brazil
Medicines sold under brand names in Brazil: ₹1,362 crore in FY26. In Q2 FY27, 53 Torrent products were waiting for approval from ANVISA, Brazil's drug regulator.
Generic medicines in the US
Off-patent medicines sold to US buyers: ₹1,363 crore in FY26, and US$44 million in Q2 FY27.
Generic medicines in Germany
Off-patent medicines sold in Germany, part of them through tenders: ₹1,249 crore in FY26. Torrent entered Germany in 2005 by buying Pfizer's marketing arm there, Heumann.
Other countries and contract manufacturing
Medicines sold in other countries, and medicines made for other companies (contract manufacturing, including JB's): ₹2,361 crore in FY26, about 17% of revenue.
The JB Pharma business
JB's brands in India, its international sales and contract manufacturing: ₹1,086 crore of revenue in Q2 FY27, of which India prescription brands ₹597 crore and international business ₹406 crore.
What it does
- Does: Makes medicines at 8 plants in India, not counting JB's (FY26 annual report)
- Does: Sells cosmetic skin-care brands through Curatio, bought in 2022 for ₹2,000 crore
- Does: Sells generic semaglutide, a diabetes and weight-loss medicine, in India as tablets and injections
- Does: Spent ₹650 crore on research and development in FY26
What it does not do
- Does not: Does not report profit by market: it reports a single segment, 'Generic Formulation Business'
- Does not: Does not rely on one buyer: no customer gave 10% or more of revenue in FY26 or FY25
- Does not: Does not make injectable semaglutide itself: a manufacturing partner makes it, and the supplier changed in 2026
13How the money flows
13How the money flows · FY26
How does money flow through Torrent Pharma?
Money in
- Revenue from operations₹13,980 cr
- Other income: a net loss (foreign-exchange gains and losses are netted in it)−₹94 cr
The company
Torrent Pharma
₹13,886 cr came in
Money out
- Materials and goods bought₹3,388 cr
- Employee costs₹2,671 cr
- Other running costs₹3,362 cr
- Depreciation, amortisation and interest₹1,504 cr
- One-off costs (mostly JB deal costs)₹89 cr
- Income tax₹734 cr
- Net profit for Torrent shareholders₹2,163 cr
- In FY26 Torrent's medicines brought in ₹13,980 crore of revenue, including JB Pharma from 21 Jan 2026.
- Other income was a net loss of ₹94 crore; foreign-exchange gains and losses are netted in it.
- Materials and goods bought took ₹3,388 crore, employees ₹2,671 crore and other running costs ₹3,362 crore.
- Depreciation and amortisation took ₹1,119 crore, interest ₹385 crore, one-off costs ₹89 crore and income tax ₹734 crore.
- What was left for Torrent's shareholders was ₹2,163 crore of profit.
14What it needs to run
14What it needs to run
What does Torrent Pharma need to run?
Plants
8 manufacturing plants in India, not counting those that came with JB Pharma (FY26 annual report).
Doctors' visits
A sales force that calls on doctors: 9,100 people in India at the end of Q2 FY27, Torrent and JB combined, against 9,400 at the end of Q1 FY27.
Regulators' approvals
Each market's drug regulator must approve a medicine before sale. ICRA says US FDA warning letters at the Dahej and Indrad plants were resolved in Aug 2023 and Aug 2024, and US launches resumed in Q1 FY26.
Research
₹650 crore spent on research and development in FY26; ₹211 crore in Q2 FY27, 4.2% of revenue.
People
18,531 employees at the end of FY26, against 17,312 a year earlier; both counts leave out JB Pharma.
Borrowed money
Non-convertible debentures (NCDs, a kind of bond) of ₹10,990 crore, issued on 19 Jan 2026 to pay for JB Pharma.
15Where growth could come from
15Where growth could come from
Where could Torrent Pharma's growth come from?
On the Q3 FY26 call (13 Feb 2026) CFO Sudhir Menon said FY27 would be the first year of the combined company, with net debt around 1 to 1.1 times EBITDA in FY28 and around 0.6 times in FY29. On the Q4 FY26 call (22 May 2026) management said it had guided for cost savings from the JB merger of up to ₹450 crore by year 3, about 20% of that in year 1.
Torrent's own India business
Working₹2,181 crore, Q2 FY27 (+20%)
Excluding JB, Torrent's India revenue grew 20% in Q2 FY27, against 12% for the Indian medicine market (PharmaTrac data), Aman Mehta said. Curatio's skin-care business grew 34%.
Status: Working, on track against what the company said.
JB Pharma
Mixed₹1,086 crore, Q2 FY27 (largely flat)
JB revenue rose 10% to ₹1,201 crore in Q1 FY27, then was largely flat in Q2 FY27: India prescription brands +7%, international −7%. The company described the effect of merging plants, divisions and sales teams as temporary. For Q1 FY27 it gave operating EBITDA of ₹424 crore for JB and ₹1,240 crore for its base business.
Status: Mixed, partly on track.
Brazil
Working+38% in rupees, Q2 FY27
Brazil revenue was R$236 million in Q2 FY27, up 20% in constant currency, the company said. 53 products were waiting for ANVISA approval.
Status: Working, on track against what the company said.
US generics
WorkingUS$44 million, Q2 FY27 (+13% in constant currency)
US revenue rose 24% in rupees in Q2 FY27. Sanjay Gupta said growth came from new launches.
Status: Working, on track against what the company said.
Germany
Behind€26 million, Q2 FY27 (−13% in constant currency)
Germany revenue fell 7% in rupees in Q2 FY27. The company cited lost tenders and a disruption at a third-party supplier.
Status: Behind, behind the company's own plan.
Semaglutide in India
Mixed32% market share, Q2 FY27 (36% in Q1)
Generic semaglutide tablets and injections. Injections were out of supply for nearly two months; Aman Mehta said a new manufacturing partner fully restored supply by Sep 2026.
Status: Mixed, partly on track.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (6)
- Q3 FY26 earnings call transcript (call 13 Feb 2026)
- Q4 FY26 earnings call transcript (call 22 May 2026)
- Press release: Torrent Pharma announces Q2 FY27 results
- Q2 FY27 earnings call transcript (call 23 Oct 2026)
- Press release: Torrent Pharma announces Q1 FY27 results (with results filing)
- Q1 FY27 earnings call transcript (call 30 Jul 2026)
16Financial strength and debt
16Financial strength · 30 Sep 2026
How much debt does Torrent Pharma have?
- Total debt₹13,874 cr
- Cash and investments₹2,986 cr
- Net debt (debt minus cash)₹10,888 cr
- Net worth (shareholders' money)₹18,373 cr
- Debt to equity
- 0.76×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings were ₹3,026 crore on 31 Mar 2025 and ₹14,798 crore on 31 Mar 2026; they include ₹10,990 crore of NCDs issued on 19 Jan 2026 for the JB deal. Lease liabilities are not included.
- Cash and liquid investments = cash, other bank balances and current investments. Debt to equity = borrowings ÷ net worth (Cityfort calculation).
- The company's own measure: net debt was 2.3 times EBITDA for FY26 (using JB's full-year EBITDA), 2.07 times at Q1 FY27 and 1.8 times at Q2 FY27.
- ICRA's own calculation put total debt at 3.3 times operating profit before depreciation, interest and tax for FY26, against 0.9 times for FY25.
- On 30 Sep 2026 goodwill was ₹3,990 crore and other intangible assets ₹23,352 crore, of total assets of ₹44,615 crore. Net worth rose from ₹8,389 crore on 31 Mar 2026 after the merger shares were issued and JB's minority stake was folded in.
Sources (9)
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
- Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26
- Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25
- Integrated Annual Report 2025-26 (FY26)
- Q2 FY27 earnings call transcript (call 23 Oct 2026)
- Q1 FY27 earnings call transcript (call 30 Jul 2026)
- Q4 FY26 earnings call transcript (call 22 May 2026)
- ICRA rationale: Torrent Pharmaceuticals Limited, change in limits (21 Jul 2026)
17Who owns it
17Who owns it · Q2 FY27
Who owns Torrent Pharma?
- Promoters (founders or parent company)60.8%
- Foreign institutions (FII)17.2%
- Indian institutions (DII)13.5%
- Public and others8.5%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (14)
- Shareholding pattern as of 31 Dec 2023
- Shareholding pattern as of 31 Mar 2024
- Shareholding pattern as of 30 Jun 2024
- Shareholding pattern as of 30 Sep 2024
- Shareholding pattern as of 31 Dec 2024
- Shareholding pattern as of 31 Mar 2025
- Shareholding pattern as of 30 Jun 2025
- Shareholding pattern as of 30 Sep 2025
- Shareholding pattern as of 31 Dec 2025
- Shareholding pattern as of 31 Mar 2026
- Shareholding pattern as of 30 Jun 2026
- Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment)
- Shareholding pattern as of 30 Sep 2026
- SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024
18What it does with profit
18What it does with profit
What does Torrent Pharma do with its profit?
Dividend per share
₹38.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Money raised · 20 Jul 2026
41,922,416 new shares issued to JB Pharma's shareholders under the merger (51 Torrent shares for every 100 JB shares); no cash was raised.
Sources (7)
- Annual Report 2021-22 (FY22)
- Annual Report 2022-23 (FY23)
- Annual Report 2023-24 (FY24)
- Annual Report 2024-25 (FY25)
- Integrated Annual Report 2025-26 (FY26)
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
- Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment)
19Governance signals
19Governance signals
What do Torrent Pharma's governance filings show?
- Auditor
- B S R & Co. LLP
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- The FY26 board's report says all related-party transactions were at arm's length and none was material under SEBI's listing rules, so no AOC-2 disclosure was needed. The holding company is Torrent Investments Ltd. Amounts were not extracted for this page.
- Credit rating
- India Ratings and Research IND AA+ (long term) affirmed; IND A1+ (commercial paper) (outlook Positive (revised from Stable)), 7 Oct 2026
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
other · 20 Jul 2026
Promoter stake fell twice, once by sale and once by dilution
Torrent Investments sold 9,944,040 shares (2.94%) on the open market on 30 Oct 2024, taking the promoter holding from 71.25% to 68.31%. On 20 Jul 2026 the 41,922,416 merger shares issued to JB's shareholders cut it to 60.78%; the promoter group's 231,185,400 shares did not change.
other · 23 Oct 2026
Stamp duty on the merger not yet provided
The Q2 FY27 results say stamp duty on the JB merger scheme is pending adjudication and has not been provided for; the amount is not disclosed.
other · 23 Oct 2026
Fire at a former JB warehouse
Torrent wrote off ₹19 crore of inventory in Q1 FY27 after a fire at an erstwhile JB warehouse; the insurance claim was under assessment and not recognised in the Q2 FY27 results.
disclosure · 23 Oct 2026
No investor presentation for Q1 or Q2 FY27
Torrent filed no investor presentation for Q1 or Q2 FY27 (NSE announcements checked to 12 Nov 2026); its results press releases carry the market-wise and JB figures.
other · 16 Oct 2026
Senior management change
Torrent told the exchanges on 16 Oct 2026 that Amal Kelshikar, an Executive Director among its senior management personnel, had resigned.
Sources (10)
- Integrated Annual Report 2025-26 (FY26)
- Intimation of credit rating: India Ratings affirms IND AA+, outlook revised to Positive
- SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024
- Shareholding pattern as of 31 Dec 2024
- Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment)
- Shareholding pattern as of 30 Sep 2026
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
- Press release: Torrent Pharma announces Q2 FY27 results
- Press release: Torrent Pharma announces Q1 FY27 results (with results filing)
- Change in senior management personnel: resignation of Executive Director Amal Kelshikar
20What the market paid
20What the market paid · price as of 11 Nov 2026
What did the market pay for Torrent Pharma on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹4,761, the NSE closing price. Market value = price × 380,367,856 shares (30 Sep 2026) = ₹181,093 crore (Cityfort calculation). P/E (price ÷ earnings) = market value ÷ profit for shareholders of the last four quarters (Q3 FY26 to Q2 FY27, ₹2,124 crore) = 85.3; JB is in two of those quarters in full, part of Q4 FY26 and not in Q3 FY26. P/B = market value ÷ net worth on 30 Sep 2026 (₹18,373 crore) = 9.9. Dividend yield = FY26 dividend of ₹38 ÷ price = 0.80%.
- Share price
- ₹4,761.00
- Market value (market cap)
- ₹181,093 cr
- P/E
- 85.3×
- P/B
- 9.9×
Source: NSE historical equity data, TORNTPHARM (EQ), 2 to 11 Nov 2026 (close on 11 Nov 2026); Shareholding pattern as of 30 Sep 2026; Integrated filing (financials) XBRL, consolidated, Q3 FY26 and 4 more
Sources (7)
- NSE historical equity data, TORNTPHARM (EQ), 2 to 11 Nov 2026 (close on 11 Nov 2026)
- Shareholding pattern as of 30 Sep 2026
- Integrated filing (financials) XBRL, consolidated, Q3 FY26
- Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26
- Integrated filing (financials) XBRL, consolidated, Q1 FY27
- Integrated filing (financials) XBRL, consolidated, Q2 FY27
- Integrated Annual Report 2025-26 (FY26)
21How it got here
21How it got here
How did Torrent Pharma get here?
1959
Milestone
Started as Trinity Laboratories
Founder U. N. Mehta started pharma operations in 1959 as Trinity Laboratories; the company was incorporated in 1972.
2005
Business-model change
Into Brazil, Germany and the US
Torrent entered Brazil in 2003, Germany in 2005 by buying Pfizer's marketing arm Heumann, and the US generics market in 2009.
2014
Business-model change
Bought brands in India
Bought Elder Pharmaceuticals' identified India branded business in 2014, and Unichem's India and Nepal business with a Sikkim plant in 2017.
2022
Crisis
US plant written down
Torrent wrote down its US liquid-medicines plant by ₹485 crore in FY22 and sold it in FY24 for ₹104 crore, booking an ₹88 crore net gain.
2022
Milestone
Bought Curatio
Bought Curatio Health Care, a cosmetic skin-care company with more than 50 brands, for ₹2,000 crore on 14 Oct 2022.
2024
Milestone
Promoter sale and diabetes brands
Torrent Investments sold 2.94% of Torrent on 30 Oct 2024. In Dec 2024 Torrent agreed to buy three empagliflozin diabetes brands from Boehringer Ingelheim, which it had co-marketed since 2022.
2026
Business-model change
JB Pharma bought and merged
Torrent took control of JB Pharma on 21 Jan 2026, two days after issuing ₹10,990 crore of NCDs; by 3 Feb it had paid ₹12,537 crore for 48.80%. The merger took effect on 8 Jul 2026, and 41,922,416 new shares went to JB's shareholders.
Sources (9)
- Integrated Annual Report 2025-26 (FY26)
- Annual Report 2021-22 (FY22)
- Annual Report 2023-24 (FY24)
- Annual Report 2022-23 (FY23)
- SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024
- Press release: Torrent Pharma agrees to acquire 3 anti-diabetes brands from Boehringer Ingelheim
- Scheme of amalgamation of J. B. Chemicals & Pharmaceuticals with Torrent: effective date 8 Jul 2026
- Record date (17 Jul 2026) for JB Chemicals shareholders under the scheme of amalgamation
- Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27)
22Sources and changes
Where every number on this page comes from
Sources (48 documents)
- S1Integrated Annual Report 2025-26 (FY26) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 1 Jun 2026
- S2Annual Report 2024-25 (FY25) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 4 Jul 2025
- S3Annual Report 2023-24 (FY24) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 29 Jun 2024
- S4Annual Report 2022-23 (FY23) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 14 Jul 2023
- S5Annual Report 2021-22 (FY22) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 4 Jul 2022
- S6Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 23 Oct 2026
- S7Integrated filing (financials) XBRL, consolidated, Q2 FY27 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 23 Oct 2026
- S8Press release: Torrent Pharma announces Q2 FY27 results · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 23 Oct 2026
- S9Q2 FY27 earnings call transcript (call 23 Oct 2026) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 29 Oct 2026
- S10Integrated filing (financials) XBRL, consolidated, Q1 FY27 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 30 Jul 2026
- S11Q1 FY27 earnings call transcript (call 30 Jul 2026) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 4 Aug 2026
- S12Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 22 May 2026
- S13Q4 FY26 earnings call transcript (call 22 May 2026) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 26 May 2026
- S14Integrated filing (financials) XBRL, consolidated, Q3 FY26 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 13 Feb 2026
- S15Press release: Torrent Pharma announces Q3 FY26 results · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 13 Feb 2026
- S16Q3 FY26 earnings call transcript (call 13 Feb 2026) · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 20 Feb 2026
- S17Integrated filing (financials) XBRL, consolidated, Q2 FY26 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 7 Nov 2025
- S18Press release: Torrent Pharma announces Q2 FY26 results · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 7 Nov 2025
- S19Integrated filing (financials) XBRL, consolidated, Q1 FY26 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 28 Jul 2025
- S20Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 20 May 2025
- S21Financial results XBRL, consolidated, Q3 FY25 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 24 Jan 2025
- S22Financial results XBRL, consolidated, Q4 FY24 and FY24 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 24 May 2024
- S23Financial results XBRL, consolidated, Q4 FY23 and FY23 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 30 May 2023
- S24Financial results XBRL, consolidated, Q4 FY22 and FY22 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 25 May 2022
- S25Shareholding pattern as of 31 Dec 2023 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 12 Jan 2024
- S26Shareholding pattern as of 31 Mar 2024 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 19 Apr 2024
- S27Shareholding pattern as of 30 Jun 2024 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 12 Jul 2024
- S28Shareholding pattern as of 30 Sep 2024 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 11 Oct 2024
- S29Shareholding pattern as of 31 Dec 2024 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 16 Jan 2025
- S30Shareholding pattern as of 31 Mar 2025 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 18 Apr 2025
- S31Shareholding pattern as of 30 Jun 2025 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 19 Jul 2025
- S32Shareholding pattern as of 30 Sep 2025 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 13 Oct 2025
- S33Shareholding pattern as of 31 Dec 2025 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 3 Jan 2026
- S34Shareholding pattern as of 31 Mar 2026 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 17 Apr 2026
- S35Shareholding pattern as of 30 Jun 2026 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 20 Jul 2026
- S36Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment) · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 20 Jul 2026
- S37Shareholding pattern as of 30 Sep 2026 · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 15 Oct 2026
- S38ICRA rationale: Torrent Pharmaceuticals Limited, change in limits (21 Jul 2026) · ICRA Limited · Tier 2: rating agency or regulator · 21 Jul 2026
- S39ICRA rationale: ratings reaffirmed; [ICRA]A1+ assigned for fresh CPs (5 Jan 2026, revised) · ICRA Limited · Tier 2: rating agency or regulator · 5 Jan 2026
- S40Intimation of credit rating: India Ratings affirms IND AA+, outlook revised to Positive · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 7 Oct 2026
- S41NSE historical equity data, TORNTPHARM (EQ), 2 to 11 Nov 2026 (close on 11 Nov 2026) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
- S42SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024 · National Stock Exchange of India (filed by Torrent Investments) · Tier 1: company or exchange filing · 30 Oct 2024
- S43Scheme of amalgamation of J. B. Chemicals & Pharmaceuticals with Torrent: effective date 8 Jul 2026 · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 8 Jul 2026
- S44Record date (17 Jul 2026) for JB Chemicals shareholders under the scheme of amalgamation · Torrent Pharmaceuticals Ltd (company IR site) · Tier 1: company or exchange filing · 7 Jul 2026
- S45Press release: Torrent Pharma agrees to acquire 3 anti-diabetes brands from Boehringer Ingelheim · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 4 Dec 2024
- S46Change in senior management personnel: resignation of Executive Director Amal Kelshikar · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 16 Oct 2026
- S47Investor presentation: audited results for Q4 FY26 and FY26 (filed with NSE) · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 22 May 2026
- S49Press release: Torrent Pharma announces Q1 FY27 results (with results filing) · National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd) · Tier 1: company or exchange filing · 30 Jul 2026
Changes to this page (v1 · 12 Nov 2026)
- v1 · 12 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.